BioMedNewsBreaks

TuesdayAug 17, 2021 12:03 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Seasoned Professional as US CEO

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has appointed life-sciences veteran and biomedical scientist Dr. Sunil Pandit as its new U.S. CEO; the appointment is effective as of Aug. 16, 2021. The company noted that Pandit will lead AnPac Bio’s U.S. research and development efforts, as well as ANPC’s commercialization efforts to drive adoption and growth of its Cancer Differentiation Analysis (“CDA”) technology. CDA is ANPC’s flagship product for cancer screening and early detection. Pandit has more than two decades of experience with leading precision medicine strategies, molecular and companion diagnostic…

Continue Reading

FridayAug 13, 2021 2:30 pm

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) State-of-the-Art IoT Products Provide Holistic View for Optimal Research

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is standing by to provide a wealth of smart devices, artificial intelligence and an integrated platform that will fully support the U.S. as it explores the benefits, risks and effects of cannabis. “U.S. researchers can benefit from RYAH Group’s state-of-the-art IoT suite of products. The technology collects, analyzes and leverages objective data throughout the research process. As a result, the company boasts one of the largest plant-based medicine databases globally with 200,000 plus registered users. The company’s ecosystem of products allows data to be collected from seed…

Continue Reading

FridayAug 13, 2021 10:13 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2021 Financial Results, Provides Business Outlook

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the quarter ended June 30, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of the second quarter, our team continued to execute on corporate, clinical and regulatory strategies to drive our Berubicin program toward regulatory approval as fast as possible. We are guided by our…

Continue Reading

FridayAug 13, 2021 9:39 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report noted that second-quarter revenue totaled $4.5 million, an increase of more than 37% year over year, and 30% over the first quarter 2021; revenue for the first half of 2021 totaled $7.9 million. Gross profit for second quarter was $3.6 million with gross margin 81%…

Continue Reading

ThursdayAug 12, 2021 12:51 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Groundbreaking Tech to Push Boundaries in Neurology Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This comes as the brain-computer interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. It is a promising approach to overcoming paralysis by decoding brain signals…

Continue Reading

WednesdayAug 11, 2021 2:16 pm

BioMedNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance,” reads a recent article discussing the company. “Cancer Differentiation Analysis (‘CDA’) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins…

Continue Reading

WednesdayAug 11, 2021 11:55 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Adjournment of Special Meeting of Stockholders

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The reason for the adjournment was to solicit more votes on a key proposal. According to the announcement, the proposal in questions calls for approval of an amendment to the company’s certificate of incorporation to increase the number of authorized shares of company common stock to…

Continue Reading

TuesdayAug 10, 2021 10:15 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnerships to Explore, Develop Proprietary Psilocybin Formulations

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has signed agreements with both Calvert Labs and Gad Consulting Services to design, execute and collaborate on exploratory studies related to Tryp's Psilocybin-for-Neuropsychiatric Disorders, or PFN(TM) (“PFN”), program. An Altasciences company, Calvert Labs has established an impressive track record of executing FDA-approved studies across a broad range of therapeutic indications. The two companies will work together to generate toxicology and blood exposure level data related to Tryp's proprietary, psilocybin-based formulation, TRP-8803; the agreement also outlines collaboration to strengthen…

Continue Reading

TuesdayAug 10, 2021 10:00 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Names Digital Therapy Visionary as Tech Advisor

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that Dr. Ken Weingardt, CEO of Audacious Digital Health, will be serving as senior clinical technology advisor. Weingardt is a clinical psychologist and has served as senior clinical director at Pear Therapeutics. Specifically,  Weingardt will work with MINDCURE's iSTRYM, the company’s digital therapeutics technology (“DTx”) platform, through near-term commercial deployment. iSTRYM is on schedule for MVP deployment in the third quarter of 2021, with commercial deployment slated for first quarter 2022. Weingardt , who most recently served as the director…

Continue Reading

FridayAug 06, 2021 2:19 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Positioned to be at Center Stage of Neurological Diagnostics Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears well-positioned to offer solutions for the growing market need in the post-pandemic world. “As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting,” reads a recent article. As such, the market for BRSF’s innovative products appears to expand. “It is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. As a commercial stage health care company…

Continue Reading